HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.

Trial Details

NCT ID
NCT01913106
Phase
PHASE1 / PHASE2
Sponsor
The Methodist Hospital Research Institute
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • HSV-tk +Valacyclovir in Combination with Brachytherapy
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • biopsy-proven local recurrence of prostate cancer without metastatic disease after the hormone therapy at least 2 year after the completion of defi…
  • Zubrod performance status 0-1
  • WBC ≥ 4,000/μl, platelets ≥ 100,000/μl
  • hemoglobin ≥ 8.5 mg/dl

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →